الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> FAK>>GSK215

GSK215

رقم الكتالوجGC64888

GSK215 عبارة عن مطهر كيناز التصاق بؤري انتقائي من PROTAC مع pDC50 يبلغ 8.4تم تصميم GSK215 بواسطة رابط لـ VHL E3 ligase ومثبط FAK VS-4718يحث GSK215 على تحلل FAK سريعًا وطويل الأمد ، مما يعطي تأثيرًا طويل الأمد على مستويات FAK وفصل الحرائك الدوائية / الديناميكيات الدوائية (PK / PD) بشكل ملحوظ

Products are for research use only. Not for human use. We do not sell to patients.

GSK215 التركيب الكيميائي

Cas No.: 2743427-26-9

الحجم السعر المخزون الكميّة
5 mg
283٫00
متوفر
10 mg
443٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect[1].

GSK215 (0.1-1000 nM; 2 hours) effectively increases the FAK degradation by >90% and determines a DC50 of 1.3 nM[1].

GSK215 (8mg/kg; i.h.) treatment shows the Cmax and tmax values of 526 ng/mL and 0.33 hours, respectively[1].

[1]. Law RP, Nunes J, Chung CW, et al. Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs [published online ahead of print, 2021 Aug 20]. Angew Chem Int Ed Engl. 2021;10.1002/anie.202109237.

مراجعات

Review for GSK215

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GSK215

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.